Pulsatile core-in-cup valsartan tablet formulations: In vitro evaluation

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 4, 2013, Pages 234-243

  Sokar, M S ^a   Hanafy, A S ^b   El Kamel, A H ^a   El Gamal, S S ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Pharos University of Alexandria   (Egypt)

Author keywords

Core in cup tablets; Double pulse; Floating; Lag time; Plug layer

Indexed keywords

EID: 84907996540     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.09.006     Document Type: Article

References (34)

1. Dalvadia, H., Patelb, J., Chronpharmaceutics, pulsatile drug delivery system as current trend. Asian J Pharm Sci 5:5 (2010), 204–230.
2. Shidhaye, S., Dhone, A., Budhkar, T., et al. Technologies in pulsatile drug delivery system. Ijapbc 1 (2012), 438–445.
3. Efentakis, M., Koligliati, S., Vlachou, M., Design and evaluation of a dry coated drug delivery system with an impermeable cup, swellable top layer and pulsatile release. Int J Pharm 311:1–2 (2006, Mar 27), 147–156.
4. Prisant, L.M., Elliott, W.J., Drug delivery systems for treatment of systemic hypertension. Clin Pharm 42:11 (2003), 931–940.
5. Wu, C.Y., Benet, L.Z., Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:1 (2005), 11–23.
6. Flesch, G., Muller, P., Lloyd, P., Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:2 (1997), 115–120.
7. Takeda, N., Maemura, K., Cardiovascular disease, chronopharmacotherapy, and the molecular clock. Adv Drug Deliv Rev 62:9–10 (2010), 956–966.
8. Hermida, R.C., Ayala, D.E., Fernández, J.R., Portaluppi, F., Fabbian, F., Smolensky, M.H., Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens 24:4 (2010), 383–391.
9. Hermida, R.C., Calvo, C., Ayala, D.E., Mojon, A., Lopez, J.E., Relationship between physical activity and blood pressure in dipper and non-dipper hypertensive patients. J Hypertens 20:6 (2002), 1097–1104.
10. Hermida, R.C., Ayala, D.E., Chayan, L., Mojon, A., Fernandez, J.R., Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 26:1 (2009), 61–79.
11. Hermida, R.C., Ayala, D.E., Fernandez, J.R., Calvo, C., Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:1 (2008), 69–76.
12. Nayak, U.Y., Shavi, G.V., Nayak, Y., Averinen, R.K., Mutalik, S., Reddy, S.M., et al. Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system. J Control Release 136:2 (2009), 125–131.
13. USP, TheUnited States pharmacopeia 35 and National formulary 30. 1st ed., 2011.
14. Chella, N., Shastri, N., Tadikonda, R.R., Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sinica B 2:5 (2012), 502–508.
15. BP, The British Pharmacopeia. 2012.
16. El Gamal, S., Naggar, V., Sokar, M., Colon targeting of mebeverine HCl from pH-dependent tablet formulations. J Am Sc 8:8 (2012), 632–638.
17. Dash, S., Murthy, P.N., Nath, L., et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 67:3 (2010), 217–223.
18. Zhang, Y., Huo, M., Zhou, J., et al. DD Solver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12:3 (2010, Sep), 263–271.
19. Singla, D., Bajaj, S., Sakhuja, N., Stability testing of pharmaceutical products. J App Pharm Sci 2:3 (2012), 129–138.
20. Patel, A., Modasiya, M., Shah, D., et al. Development and in vivo floating behavior of verapamil HCl intragastric floating tablets. AAPS PharmSciTech 10:1 (2009), 310–315.
21. Bolton, S., Bon, C., Statistical inference: estimation & hypothesis testing. 4th ed. Pharmaceutical Statistics Practical & Clinical Applications, vol. 135, 2004, Marcel Dekker Inc, New York, Basel, 131.
22. Shrivastava, A.R., Ursekar, B., Kapadia, C.J., Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv 6:1 (2009, Jan), 28–37.
23. Cui, J.H., Enhanced oral bioavailability of novel mucoadhesive pellets containing valsertan prepared by a dry powder-coating technique. Int J Pharm 434:1–2 (2012, June 9), 325–333.
24. Ferrero, C., Muñoz, N., Velasco, M.V., et al. Disintegrating efficiency of croscarmellose sodium in a direct compression formulation. Int J Pharm 147:1 (1997), 11–21.
25. Lerk, C.F., Bolhuis, G.K., Smallenbroek, A.J., et al. Interaction of tablet disintegrants and magnesium stearate during mixing. II. Effect on dissolution rate. Pharm Acta Helv 57:10–11 (1982), 282–286.
26. Krishna Rao, K., Ha, C.-S., pH Sensitive hydrogels based on acryl amides and their swelling and diffusion characteristics with drug delivery behavior. Polymer Bull 62:2 (2009), 167–181.
27. Michailova, V., Titeva, S., Kotsilkova, R., et al. Influence of aqueous medium on viscoelastic properties of carboxymethylcellulose sodium, hydroxypropylmethyl cellulose, and thermally pre-gelatinized starch gels. Colloids Surf A 149:1–3 (1999), 515–520.
28. Sangalli, M.E., Maroni, A., Foppoli, A., et al. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances. Eur J Pharm Sci 22:5 (2004), 469–476.
29. Singh, B.N., Kim, K.H., Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 63:3 (2000), 235–259.
30. Density of chemicals, 2012 12 Mar Available from http://www.inchem.org/documents/icsc/ecs0827.htm.
31. Bisht, R., Chronomodulated drug delivery system: a comprehensive review on the recent advances in a new sub-discipline of chronopharmaceutics. Asian J Pharm Sci, 5(1), 2011, 1.
32. Peppas, N.A., Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:4 (1985), 110–111.
33. Langenbucher, F., Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 24:12 (1972, Dec), 979–981.
34. Papadopoulou, V., Kosmidis, K., Vlachou, M., et al. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm 309:1–2 (2006), 44–50.